Cardiovascular Drug Discovery&Development Summit to Feature Next Generation Therapeutics on February 10&11 in San Diego, CA
PR Newswire, Tuesday, October 15, 2002 at 08:46
SAN DIEGO, Oct 15, 2002 /PRNewswire via COMTEX/ -- The cardiovascular research field will convene to discuss the latest efforts in drug discovery and clinical development for the next generation of therapeutics at the first-ever,"Cardiovascular Drug Discovery&Development Summit,"which will take place in San Diego, CA on February 10&11, 2003, announces Strategic Research Institute.
Highlights of the meeting include:
--"Clinical Development of Crestor,"by AstraZeneca
--"Nuclear Receptor PPAR in Macrophages Results in Reduced Inflammatory
Response and Atherosclerotic Lesion,"by The Salk Institute
--"Inhibition of ApoB-100 with Antisense Technology as a Therapeutic
Strategy for the Treatment of Hyperlipidemias,"Isis Pharmaceuticals
List of presenters include: AstraZeneca, Bristol-Myers Squibb, Eli Lilly&Co., Millennium Pharmaceuticals, Pharmacia Corporation, Procter&Gamble Pharmaceuticals, Atherogenics, Collateral Therapeutics, CV Therapeutics, Isis Pharmaceuticals, Myogen, Sequenom, Texas Biotechnology, Purdue University, Salk Institute, Scripps Research Institute, and Southwestern Medical Center.
To receive the full agenda and/or register for the conference, please contact Jon E. Liong of Strategic Research Institute at jliong@srinstitute.com or 212-967-0095, x243 (please include name, corporate affiliation, mailing address, and fax number).
For information on exposition, or to sponsor a function please contact Mark Alexay at malexay@srinstitute.com. |
